The FKBP4 antibody targets the FK506-binding protein 4 (FKBP4), also known as FKBP52. a member of the immunophilin protein family. FKBP4 acts as a molecular chaperone, regulating diverse cellular processes through its peptidyl-prolyl isomerase (PPIase) activity. It interacts with Hsp90 to modulate the function of client proteins, including steroid hormone receptors (e.g., androgen and glucocorticoid receptors), influencing their ligand-binding affinity and subcellular trafficking. FKBP4 also plays roles in mTOR signaling, apoptosis, and stress response pathways.
Antibodies against FKBP4 are widely used in research to study its expression, localization, and interactions in physiological and pathological contexts. They are employed in techniques like Western blotting, immunoprecipitation, and immunohistochemistry. Dysregulation of FKBP4 has been implicated in cancers (e.g., prostate, breast), neurodegenerative diseases (e.g., Alzheimer’s via Tau regulation), and reproductive disorders, making its antibody a critical tool for exploring disease mechanisms. Studies also highlight its potential as a therapeutic target, particularly in hormone-resistant cancers. Researchers utilize FKBP4 antibodies to dissect its dual roles in protein folding and signal transduction, offering insights into cellular stress adaptation and drug resistance.